Eguchi K
Department of Internal Medicine and Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Curr Opin Oncol. 1995 Jul;7(4):316-9. doi: 10.1097/00001622-199507000-00004.
Chronic anemia associated with cancer often causes poor quality of life and is often exacerbated by intensive treatment. In recent controlled trials, recombinant human erythropoietin (rhEpo) proved to be well tolerated and effective in amelioration and reduction of transfusion requirements of cancer-associated anemia. Double-blind placebo-controlled trials of rhEpo in patients undergoing allogenic, but not autologous, bone marrow transplantation showed significant acceleration of the reconstitution of erythropoiesis. Multivariate analysis revealed that serum erythropoietin levels of 100 mU/mL or greater and an increase in hemoglobin by at least 0.5 g/dL was a probable response; conversely, a serum ferritin level of 400 ng/mL or greater after 2 weeks indicated a poor response to rhEpo therapy. Further studies are needed to define patient populations in whom cost-effective rhEpo therapy is justified.
与癌症相关的慢性贫血常常导致生活质量低下，并且在强化治疗时往往会加重。在最近的对照试验中，重组人促红细胞生成素（rhEpo）被证明耐受性良好，并且在改善和减少癌症相关性贫血的输血需求方面有效。对接受同种异体而非自体骨髓移植的患者进行的rhEpo双盲安慰剂对照试验表明，红细胞生成的重建显著加速。多变量分析显示，血清促红细胞生成素水平达到或高于100 mU/mL且血红蛋白至少增加0.5 g/dL可能是一种反应；相反，2周后血清铁蛋白水平达到或高于400 ng/mL表明对rhEpo治疗反应不佳。需要进一步研究来确定哪些患者群体适合进行具有成本效益的rhEpo治疗。
